Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Interest Expenses (2016 - 2026)

Amphastar Pharmaceuticals has reported Interest Expenses over the past 13 years, most recently at $6.6 million for Q4 2025.

  • For Q4 2025, Interest Expenses rose 3.19% year-over-year to $6.6 million; the TTM value through Dec 2025 reached $25.5 million, down 16.02%, while the annual FY2025 figure was $25.5 million, 16.02% down from the prior year.
  • Interest Expenses for Q4 2025 was $6.6 million at Amphastar Pharmaceuticals, up from $6.3 million in the prior quarter.
  • Over five years, Interest Expenses peaked at $13.7 million in Q3 2023 and troughed at $86000.0 in Q2 2021.
  • A 5-year average of $4.3 million and a median of $4.9 million in 2023 define the central range for Interest Expenses.
  • Biggest five-year swings in Interest Expenses: skyrocketed 2320.85% in 2023 and later tumbled 51.12% in 2024.
  • Year by year, Interest Expenses stood at $168000.0 in 2021, then soared by 214.29% to $528000.0 in 2022, then surged by 1690.91% to $9.5 million in 2023, then crashed by 32.05% to $6.4 million in 2024, then rose by 3.19% to $6.6 million in 2025.
  • Business Quant data shows Interest Expenses for AMPH at $6.6 million in Q4 2025, $6.3 million in Q3 2025, and $6.3 million in Q2 2025.